A randomized trial found that patients with painful hallux rigidus (#arthritis of the big toe joint) who underwent first metatarsophalangeal joint (MTPJ) arthrodesis reported substantially less walking pain after 12 months compared with watchful waiting. The findings reinforce joint fusion #surgery as the preferred treatment for some patients with painful hallux rigidus. https://t.co/rsAoGCGIX8
The 12-month results of the HARD trial have now been published in Annals of Internal Medicine.
The HARD trial is the first randomized controlled trial to compare surgery with watchful waiting in patients with symptomatic hallux rigidus, addressing a decades-old question in the treatment of the painful big toe.
Led by principal investigator Mikko Miettinen, the trial compared first metatarsophalangeal joint arthrodesis with watchful waiting. FICEBO core members Lasse Rämö, senior author of the publication, and Tuomas Lähdeoja, co-author, also had the opportunity to contribute to the trial.
On our website, you can read more about the trial, hear comments from the research team, and explore the key findings from the newly published results.
Read the full news article here: https://t.co/tgxzdFKqg0
Here are three recent papers on spine-related limb pain & serious pathology in the neck ���️
Scroll down⏬️
1. Stop guessing: A clinician's guide to demystifying spine-related arm pain in primary care.
https://t.co/sXi3mxgwJn
Polymyalgia rheumatica is the most common inflammatory disease in patients of 50 and over.
How is it diagnosed and why is this condition missed?
#MedEd
https://t.co/fDP9AE5eTd
Great to see our trial on swimming for chronic low back pain 'making waves' in the media...
Covered by The Conversation this morning!
Big thanks to Dr Deb Wareham for doing a stellar job on driving this important work!
https://t.co/nYb0cM3omB
@MarkHancockPT@CGMMaher@hjenk001
Just published: How we should be educating clinicians in #EBM concepts in 2026. Includes guidance to put much less emphasis on critical appraisal and much more on understanding magnitudes of effect and quality of evidence, and use of #AI in education.
https://t.co/j2BsXve9Pp
🤔 Are clinical guidelines for knee osteoarthritis failing the global population?
This months Editors Choice (Clinical) looked at 241 RCTs to reveal some blind spots 👇
Read for free from Low et al. - https://t.co/mlc0CJd3J7
@DrDanilo_Silva@DrChrisBarton@AllisonEzzat
#Lancet Commission report on Public Policy and Health in the first #Trump administration presaged events in the second: adverse impact of income inequality on health; increasing coverage barriers, increased #uninsured; environmental rollbacks increased pollution-related #mortality.
https://t.co/OqdrRx0ojq
Effectiveness of a blended care intervention in physiotherapy with exercise and education for patients with hip or knee osteoarthritis (SmArt-E): a multicentre pragmatic randomized controlled trial - Osteoarthritis and Cartilage https://t.co/v945ycSRZh
📊 Research Summary: Self-directed #CBT-CP with asynchronous coaching modestly reduced pain interference at 4 months vs clinician-delivered therapy, with durable benefits and higher session completion rates.
https://t.co/bBG0s1SMyn
🎉 Our first study estimating the smallest worthwhile effect of ACL reconstruction is now published in the Journal of Physiotherapy (IF 9.4)!
🔗 https://t.co/hlGc9bDUvQ
Grateful to A/Prof @zadro_josh who leads this work and our co-authors
@syd_health@SACM_AU@SydneySPH
🔥 Just out!
The first of OAC's Osteoarthritis "Fundamental series" covers #diagnosis and #assessment
A clinician’s diagnosis is a vital step to facilitate access to and engagement
with treatment.
Read more from Lauren King and Abhishek Abhishek here: https://t.co/2CkgBboKZK
📈Knee arthroplasty in OECD countries has hit a tipping point
New study by Backes, Pabinger, Lothaller & Geissler tracks 25 countries over 17 years and found that patients under 65 now make up >50% of all procedures - up from ~37% in 2005.
Read for free: https://t.co/YnjhXh1NYz
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO